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MaOBJECTIVES This study sought to assess the rate and predictors of 1-year restenosis after drug-eluting stent
implantation for femoropopliteal (FP) lesions in patients with peripheral arterial disease.
BACKGROUND Zilver PTX, a paclitaxel-eluting stent for FP lesions, provides superior outcomes to angioplasty and
bare-metal stents in clinical trials. However, its real-world outcomes and the associated features remain unclear.
METHODS This was a prospective multicenter study enrolling 831 FP lesions (797 limbs, 690 patients) treated by Zilver
PTX implantation. The primary endpoint was 1-year restenosis. Secondary endpoints included major adverse limb event
and stent thrombosis.
RESULTS Mean lesion length was 17  10 cm. One-year restenosis, major adverse limb event, and stent thrombosis
rates were 37%, 22%, and 2%, respectively. The generalized linear mixed model showed that lesion length $16 cm
assessed by angiography and distal external elastic membrane area #27 mm2 and minimum stent area #12 mm2 assessed
by intravascular ultrasound were independent risk factors for restenosis. One-year restenosis rates were 15% in cases
with none of these risk factors and 50% in those with $2 risk factors.
CONCLUSIONS The current study demonstrated 1-year real-world outcomes after drug-eluting stent treatment for
FP lesions, including challenging ones in clinical practice. Lesion length, external elastic membrane area, and minimum
stent area were independent predictors for restenosis. (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery—
Prospective Multicenter Registry [ZEPHYR]; UMIN000008433) (J Am Coll Cardiol Intv 2015;8:1105–12)
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ABBR EV I A T I ON S
AND ACRONYMS
CI = conﬁdence interval
DES = drug-eluting stent(s)
DUS = duplex ultrasonography
EEM = external elastic
membrane
EVT = endovascular therapy
FP = femoropopliteal
IVUS = intravascular
ultrasound
MALE = major adverse limb
event
MSA = minimum stent area
ROC = receiver-operating
characteristic
ST = stent thrombosis
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1106Z ilver PTX (Cook Medical, Blooming-ton, Indiana) paclitaxel-eluting stent,a recently developed drug-eluting
stent (DES), has shown superior long-term
outcomes for femoropopliteal (FP) lesions
relative to balloon angioplasty and
provisional bare-metal stent placement in
clinical trials (1,2). However, the population
in these trials seems less severe than a real-
world population in clinical practice. To
date, real-world outcomes of Zilver-PTX im-
plantation for FP lesions including chal-
lenging ones remain to be systematically
studied. Therefore, we examined the rate
and predictors of 1-year restenosis after DES
implantation for FP lesions in patients with
peripheral arterial disease in clinical settings.METHODS
The ZEPHYR (Zilver PTX for the Femoral Artery and
Proximal Popliteal Artery) registry was a prospective
and multicenter study, enrolling patients who had
symptomatic peripheral arterial disease due to FP
lesions and were treated with Zilver PTX implantation
between July 2012 and June 2014. A total of 26 centers
participated (Online Appendix). The study was in
accordance with the Declaration of Helsinki, was
approved by the ethics committee of each partici-
pating hospital, and was registered in the University
Hospital Medical Information Network Clinical Trial
Registry. Written informed consent was obtained
from every participant.SEE PAGE 1113STUDY POPULATION. Patients with symptomatic
peripheral artery disease were screened by noninva-
sive tests to detect limb ischemia and presence of FP
lesions. Study enrollment occurred only after satis-
fying the arteriographic inclusion/exclusion criteria
described herein. A total of 831 FP lesions (797 limbs,
n ¼ 690) with Zilver PTX implantation were ﬁnally
enrolled.
ENDOVASCULAR PROCEDURE. The indication for
revascularization included symptomatic disease with
>50% diameter stenosis determined by angiography
and mean pressure gradient >10 mm Hg determined
with a 4-F diagnostic catheter. Decision on Zilver PTX
implantation was left to the discretion of physicians.
For endovascular therapy (EVT), a 6-F sheath was
inserted into the femoral artery mostly with a
contralateral approach. After 5,000-U heparin
infusion, 0.035- or 0.014-inch guidewires were usedto cross the lesion. Prior to stent implantation, the
guidewire was exchanged for a 0.035-inch one,
compatible with the stent delivery system. A ﬁnal
post-dilation was performed for at least 30 s with a
noncompliant balloon the size of which was equiva-
lent to distal vessel diameter. Dual antiplatelet ther-
apy with aspirin and either ticlopidine or clopidogrel
was recommended to start at least 1 week before and
continue for at least 2 months after the stent implan-
tation in accordance with the package insert. Anti-
platelet and anticoagulant regimens were used
according to the physician’s discretion based on
patient’s condition.
In the current study, intravascular ultrasound
(IVUS) was performed to record the data on vessel
characteristics immediately after wire crossing and at
end of the procedure when possible. IVUS was per-
formed with a commercially available IVUS console
and phased-array 20-MHz (Eagle Eye Gold, Volcano
Corp., Rancho Cordova, California) or mechanical-
scan 40-MHz (OptiCross, Boston Scientiﬁc, Marl-
borough, Massachusetts) IVUS catheters. IVUS was
manually pushed forward at a constant speed of
10 mm/s. IVUS and ﬂuoroscopy images were recorded
simultaneously to link IVUS images with location
using ruler for off-line analysis. External elastic
membrane (EEM) area before ballooning and minimal
stent area (MSA) (i.e., the smallest cross-sectional
area within the stent), after post-dilation were
assessed. In occluded cases, IVUS was also used if the
wire was in a true lumen or subintimal space. In the
current study, IVUS data as well as angiographic data
at baseline were evaluated at each participating
institute and not by the core laboratory review.
FOLLOW-UP PROTOCOL. All participants were asked
to visit centers at 1, 3, 6, and 12 months after EVT. At
each visit, ischemic symptoms and ankle-brachial
index were evaluated and duplex ultrasonography
(DUS) was routinely conducted to evaluate patency.
At 12 months after EVT, patients who had not
received any reintervention or major amputation
were scheduled for readmission at the study institu-
tion and underwent follow-up angiography for the
treated lesions when possible. The follow-up angio-
graphic data were reviewed at a core laboratory using
CAASV software (version 5.7, Pie Medical Imaging,
Maastricht, the Netherland). Target lesion revascu-
larization was conducted for $50% diameter stenosis
within 5 mm of the target lesion after documentation
of recurrent clinical symptoms.
ENDPOINTS. The primary endpoint was 12-month
restenosis rate assessed by DUS or follow-up angiog-
raphy, with a tolerance of 2 months. Restenosis
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1107was deﬁned as recurrence of $50% diameter stenosis
determined by angiography or a peak systolic velocity
ratio >2.4 by DUS (3). Requirement of any reinter-
vention or major amputation (deﬁned as surgical
limb excision above the ankle) within 1 year was
automatically included in restenosis. Secondary
endpoints were major adverse limb event (MALE)
and stent thrombosis (ST). MALE was deﬁned as
major amputation or any reintervention, including
both surgical or endovascular reintervention. ST
was determined when apparent occlusion met
the following criteria: 1) initial procedural success;
2) rapid symptom occurrence; 3) thrombus present at
procedure; and 3) lesion resolved with <50% diam-
eter narrowing by thrombolysis therapy.
STATISTICAL ANALYSIS. Data are shown as means 
SD for continuous variables or as percentages for
dichotomous variables, unless otherwise mentioned.
A p of <0.05 was considered signiﬁcant. One-year
restenosis incidence in the overall population was
calculated as pMALE þ (1 – pMALE)  pRestenosis, where
pMALE and pRestenosis indicate 1-year MALE prevalence
in the overall population and 1-year restenosis prev-
alence in the MALE-free subgroup, respectively.
Because cases exist that completed 1-year follow-up
without MALE but failed to have patency assessed
at 12  2 months, we estimated pRestenosis on the basis
of the hypothesis that cases with missing data on
patency are subject to the same risk as the remaining
observed cases, which is similar to the Kaplan-Meier
estimation. Therefore, pRestenosis was calculated to
be equal to restenosis prevalence in the population
that completed 1-year follow-up without MALE and
had patency assessed at 12  2 months. Similarly,
pMALE in the overall population (including cases with
death or dropout within 1 year) was calculated to be
equal to the MALE prevalence in the population that
completed 1-year follow-up without death or dropout
within 1 year. The 95% conﬁdence interval (CI) of
1-year endpoint incidence rate was estimated by
100,000-time bootstrap resampling. The association
of baseline characteristics with restenosis, as well as
MALE, was assessed with their odds ratios, which
were derived from the generalized linear mixed
model with a logit link function. In the model, the
interinstitution variability and the intersubject vari-
ability were treated as random effects, whereas the
following baseline characteristics were treated as
ﬁxed effects: critical limb ischemia; restenotic lesion;
reference vessel diameter; lesion length; chronic total
occlusion; calciﬁcation; IVUS-evaluated EEM area;
angiography-evaluated post-treatment stenosis; and
IVUS-evaluated MSA. An odds ratio of a baseline
characteristic without adjustment for other baselinecharacteristics, named an “unadjusted” odds ratio,
was obtained from the mixed model in which the
ﬁxed effect was the covariate alone. We conve-
niently named this model the “univariate” model. On
the other hand, an odds ratio of a baseline char-
acteristic with adjustment for other baseline charac-
teristics, named the “adjusted” odds ratio, was
obtained from the model whose ﬁxed effects in-
cluded the covariate of interest plus other covariates.
This model was named the “multivariate” model. The
predictive ability was assessed by the area under
the receiver-operating characteristic (ROC) curve.
For its drawing, sensitivity, p{X $ c j D ¼ 1}, and
speciﬁcity, p{X < c j D ¼ 0}, were calculated as
p{X $ c}  p{D ¼ 1 j X $ c} / p{D ¼ 1} and p{X < c} 
p{D ¼ 0 j X < c} / p{D ¼ 0}, respectively, where X
denotes a predictive test of interest, c indicates its
cutoff value, and D is a binary indicator of restenosis.
p{D ¼ 1 j X $ c}, p{D ¼ 1}, p{D ¼ 0 j X < c}, and p{D ¼ 0}
were estimated as described herein. Monotonicity of
the calculated sensitivity and speciﬁcity in X was
guaranteed by using the nearest neighbor estimation
of the bivariate distribution (4). The difference of the
area under the ROC curve was tested by 100,000-time
bootstrap resampling. Risk stratiﬁcation analysis was
additionally performed according to the number
of accumulated risk factors for restenosis. The
cumulative incidence of ST was estimated by the
Kaplan-Meier method. The association of number of
antiplatelet agents (aspirin, thienopyridines, and cil-
ostazol) with ST was evaluated by the Cox regression
model with mixed effects. In the model, the interin-
stitution variability and the intersubject variability
were treated as random effects, whereas the number
of agents during the follow-up period was entered as
a time-dependent covariate with ﬁxed effects. Pro-
portional hazards assumption was made on the basis
of the ﬁnding that the time-by-covariate interaction
term additionally included in the model did not
demonstrate statistical signiﬁcance. Statistical anal-
ysis was performed by R (version 3.1.0, R Core Team,
Vienna, Austria).
RESULTS
Baseline characteristics of the study population are
shown in Table 1, indicating their poor comorbidity
status. One-third of the population presented critical
limb ischemia. Mean lesion length was 17  10 cm;
24% were restenotic lesions, and 15% were in-stent
restenosis. A total of 467 limbs (58%) were classiﬁed
as TASC (Trans-Atlantic Inter-Society Consensus)
II class C/D. Perioperative in-hospital complications
were observed in 4.9% (34 of 690), including
TABLE 1 Baseline Characteristics
Patient characteristics, n ¼ 690
Age, yrs 73.6  8.8
Male 490 (71)
BMI, kg/m2 22.1  3.4
Hypertension 585 (85)
Hyperlipidemia 483 (70)
Diabetes mellitus 477 (69)
Renal insufﬁciency, <30 ml/min/1.73 m2 258 (37)
Regular hemodialysis 209 (30)
History of smoking, past/current 434 (63)/138 (20)
Cardiovascular disease 347 (50)
Cerebrovascular disease 123 (18)
Number of antiplatelet agents 2.2  0.5
Lower limb characteristics, n ¼ 797
Critical limb ischemia 255 (32)
Lesion characteristics, n ¼ 831
Chronic total occlusion 378 (45)
Restenosis 198 (24)
In-stent restenosis 124 (15)
Lesion length, cm 17  10
Distal vessel diameter, mm 5.2  1.0
Percentage of stenosis 90  15
Calciﬁcation 541 (65)
No below-the-knee runoff vessel 56 (7)
IVUS-evaluated distal EEM area, mm2, n ¼ 583 28  10
Percentage of stenosis after stent implantation 4  9
IVUS-evaluated MSA, mm2, n ¼ 597 15  4
Values are mean  SD or n (%). Lesion characteristics were assessed by angiog-
raphy, except for distal EEM area and MSA, which were evaluated by IVUS.
BMI ¼ body mass index; EEM ¼ external elastic membrane; IVUS ¼ intravascular
ultrasound; MSA ¼ minimum stent area.
FIGURE 1 1-Year Incidence of Restenosis and MALE
Error bars represent 95% conﬁdence interval. Major adverse limb
events (MALE) were automatically included in restenosis for the
analysis.
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1108hematoma (n ¼ 16), distal embolism (n ¼ 8), pseu-
doaneurysm (n ¼ 4), and others (n ¼ 6). Pre- and post-
treatment IVUS data were available in 586 lesions
(71%) and 632 lesions (76%), respectively.
ONE-YEAR INCIDENCE OF CLINICAL OUTCOMES.
Of a total of 690 enrolled patients, 64 patients (9%)
died and 44 (6%) dropped out by the end of the study.
Of the remaining 697 lesions (84%) in 592 patients
(86%), 150 lesions experienced MALE, whereas 547
were free from MALE. Of the 547 MALE-free lesions,
481 lesions had their patency assessed at 12  2
months, whereas 66 did not. Patency was assessed by
the core laboratory–reviewed angiography in 208 of
the 481 lesions (43%). Figure 1 shows the estimated
clinical outcomes at 1 year. One-year incidence of
restenosis in the overall population was estimated to
be 37% (95% CI: 33 to 41), whereas 1-year MALE was
observed in 22% (95% CI: 19 to 25), indicating that
MALE accounted for 58% in lesions with restenosis.
PREDICTORS FOR RESTENOSIS. Table 2 shows the
logistic regression analysis used to investigate the
predictors for 1-year restenosis. When angiographicdata were used for analysis, reference vessel diameter
(<4.5 cm) and lesion length ($8 cm) were indepen-
dent predictors for restenosis, whereas lesion length
($16 cm), distal EEM area (#27 mm2), and MSA
(#12 mm2) were independent predictors in analysis
with angiographic and IVUS data. The use of IVUS data
provided a larger area under the ROC curve for pre-
dicting restenosis (0.70 vs. 0.65, p ¼ 0.040). In strat-
iﬁcation analysis, 1-year restenosis rate was as low as
15% in cases with none of these risk factors, whereas it
reached 50% in those with $2 risk factors (Figure 2).
We supplementarily analyzed the association of
these risk factors with MALE, using the generalized
linear mixed model with a logit link function. In the
univariate analysis, small reference vessel diameter
(<4.5 mm), small distal EEM area (#27 mm2), and
small MSA (#12 mm2), but not the other baseline
characteristics, were signiﬁcantly associated with
MALE (all p < 0.05). In the multivariate model in
which these 3 variables with signiﬁcance were
entered as ﬁxed effects, only small distal EEM area
(#27 mm2) had a signiﬁcant and independent associ-
ation with MALE; its adjusted odds ratio was 6.09
(95% CI: 2.11 to 17.6).
ST INCIDENCE. Cumulative ST incidence is shown in
Figure 3A, revealing its linear increase over time
during the 12-month follow-up. The incidence at
TABLE 2 Uni- and Multivariate Analysis for Loss of Patency Assessed With Angiographic and IVUS Data
Unadjusted Odds Ratio in
Univariate Model
Adjusted Odds Ratio in Multivariate Model
With Angiographic Data
Adjusted Odds Ratio in Multivariate Model
With Angiographic and IVUS Data
Critical limb ischemia 1.03 (0.67–1.59) 0.98 (0.62–1.57) 0.99 (0.54–1.79)
Restenotic lesion
De novo 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Restenosis after angioplasty 1.35 (0.68–2.69) 1.47 (0.73–2.96) 0.96 (0.35–2.64)
Restenosis after stenting 1.36 (0.80–2.31) 1.23 (0.69–2.20) 1.56 (0.75–3.26)
Angiography-evaluated data
Reference diameter (distal)
Q4, $6.0 cm 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Q3, 5.1–5.9 cm 1.73 (0.96–3.10) 1.61 (0.87–2.97) 1.64 (0.77–3.51)
Q2, 4.5–5.0 cm 1.22 (0.72–2.09) 1.06 (0.62–1.81) 0.80 (0.40–1.60)
Q1, #4.4 cm 2.08 (1.16–3.74)* 1.81 (1.02–3.23)* 1.08 (0.49–2.40)
Lesion length
Q1, #7 cm 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
Q2, 8–15 cm 2.18 (1.19–3.98)* 2.10 (1.13–3.88)* 1.71 (0.80–3.64)
Q3, 16–24 cm 3.63 (1.92–6.87)* 3.08 (1.59–6.00)* 3.16 (1.37–7.24)*
Q4, $25 cm 3.15 (1.69–5.86)* 2.68 (1.35–5.32)* 2.78 (1.18–6.57)*
Chronic total occlusion 1.75 (1.16–2.62)* 1.27 (0.81–2.00) 0.92 (0.52–1.62)
Calciﬁcation 1.18 (0.79–1.77) 1.09 (0.70–1.72) 1.35 (0.77–2.39)
Post-treatment stenosis
0% 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
0%–25% 0.87 (0.47–1.61) 0.86 (0.50–1.50) 0.87 (0.40–1.91)
<50% 0.70 (0.16–3.05) 0.86 (0.19–3.88) 0.98 (0.16–5.90)
IVUS-evaluated data
Distal EEM area
Q4, $34 mm2 1.00 (Ref) — 1.00 (Ref)
Q3, 28–33 mm2 1.92 (0.92–3.99) — 1.72 (0.78–3.80)
Q2, 22–27 mm2 3.20 (1.56–6.57)* — 2.34 (1.04–5.25)*
Q1, #21 mm2 6.18 (2.84–13.4)* — 4.41 (1.84–10.6)*
Post-treatment MSA
Q4, $18 mm2 1.00 (Ref) — 1.00 (Ref)
Q3, 15–17 mm2 1.71 (0.86–3.42) — 0.99 (0.45–2.19)
Q2, 13–14 mm2 2.04 (1.00–4.13)* — 1.07 (0.48–2.41)
Q1, #12 mm2 5.16 (2.44–10.9)* — 2.38 (1.02–5.51)*
Values are odds ratio for restenosis (95% conﬁdence interval). Dashes indicate that data are not available. *p < 0.05.
EEM ¼ external elastic membrane; Ref ¼ reference; other abbreviations as in Table 1.
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110912 months was estimated to be 2%. During the
follow-up period, 11 patients interrupted their anti-
platelet agents. The reason for the interruption
was self-interruption (n ¼ 4); gastrointestinal hem-
orrhage (n ¼ 2); surgery for renal cancer, major
amputation, and peritoneal dialysis catheter (n ¼ 1,
respectively); bone fracture due to falling (n ¼ 1); and
unspeciﬁed (n ¼ 1). The interruption of antiplatelet
agents was signiﬁcantly associated with an increased
ST risk (Figure 3B).
DISCUSSION
SUMMARY OF THIS STUDY. The current study
demonstrated 1-year real-world outcomes of Zilver
PTX treatment for FP lesions including challenging
ones seen in clinical practice. The incidence ofrestenosis varied across lesion characteristics. Lesion
length $16 cm, distal EEM area #27 mm2, and
MSA #12 mm2 were independent risk factors for
restenosis. One-year restenosis rate in lesions
without these risk factors was 15%, whereas it was
50% in those with $2 risk factors. To the best of our
knowledge, this is the ﬁrst study investigating clinical
outcomes after Zilver PTX implantation for FP lesions
in clinical settings and the associated risk factors
including IVUS-evaluated parameters.
CURRENT STATUS OF ZILVER PTX. Zilver PTX is a
recently developed DES for FP lesions. Clinical trials
showed that Zilver PTX provides better long-term
outcomes than balloon angioplasty and provisional
bare-metal stent placement (1,2). However, the pop-
ulation in these trials was limited; FP lesions treated
FIGURE 2 Restenosis and MALE Incidence According to
Number or Risk Factors for Restenosis
Risk factors for restenosis were lesion length of $16 cm, external
elastic membrane area of #27 mm2, and minimum stent area
of #12 mm2, which were determined by multivariate analysis
using angiographic and intravascular ultrasound parameters
(Table 2). Error bars represent 95% conﬁdence interval.
MALE ¼ major adverse limb events.
FIGURE 3 Cumulative ST Incidence
(A) The cumulative stent thrombosis (ST) incidence rate in cases
keeping antiplatelet therapy during the follow-up period (n ¼
820) and its standard error are shown. The incidence was esti-
mated by the Kaplan-Meier method after excluding cases with
antiplatelet therapy interrupted during the study period (n ¼ 11),
the corresponding incidence at 1 year was 15  10%. Note that
the cumulative incidence of which was increased linearly even
when the subjects were limited to those keeping antiplatelet
therapy. (B) The hazard ratio of number of antiplatelet agents for
ST and the 95% conﬁdence interval, which were estimated in the
Cox model in which the number of antiplatelet agents was
treated as a time-dependent covariate, are shown.
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1110in clinical settings are more varied than those in
the trials. Real-world clinical outcomes of DES im-
plantation for FP lesions remained unrevealed. Pre-
vious studies on catheter treatment including
coronary and peripheral interventions indicate that
durability of vessel after catheter treatment are
largely inﬂuenced by lesion characteristics such as: 1)
vessel diameter and morphology (easy to dilate or
not) (5,6); 2) lesion type (new or not) (7); and 3) lesion
length (short or long) (8). However, to date, little is
known about the association of these lesion charac-
teristics with clinical outcomes after DES implanta-
tion for FP lesions.
FINDINGS AND INTERPRETATIONS. In the current
study, 1-year restenosis rate in the overall population
was 37%, which was apparently worse than that re-
ported in previous Zilver PTX trials. This discrepancy
might come from the severity of the current study
population’s conditions. The current study included
more complex lesions, reﬂecting the real-world set-
tings, which might lower the patency rate. Indeed, we
revealed that the restenosis risk varied across lesion
characteristics and that the subgroup without
complexity had a low restenosis risk, which were
comparable to that reported in previous trials.
Another possible explanation for the discrepancy in
the reported restenosis rate might be the statistical
methodology for its evaluation. Previous studies
adopted the Kaplan-Meier method for their patencyanalysis. However, this method is originally for
right-censored data and is not suitable for the anal-
ysis including left-censored data such as restenosis.
This misapplication of the Kaplan-Meier method
might underestimate the restenosis rate in previous
reports.
The risk analysis revealed that lesion length was
independently associated with future restenosis,
with the threshold of $16 cm. Given that lesion length
of $25 cm had a similar restenosis risk to that of 16 to
w24 cm, the restenosis risk might not increase line-
arly in Zilver PTX implantation for FP lesions. Sup-
plementary analysis showed that long lesion length
was not signiﬁcantly associated with future risk of
MALE. However, the number of events observed was
smaller than for restenosis, and therefore a smaller
statistical power might cause the current nonsigniﬁ-
cant association. Future studies that have a larger
sample size and that can observe more MALE events
will be needed to conclude that lesion length is not
associated with MALE risk at all.
PERSPECTIVES
WHAT IS KNOWN? Zilver PTX has not totally relieved
restenotic risk after EVT for FP lesions.
WHAT IS NEW? Restenosis occurs at a certain frequency in
clinical practice.
WHAT IS NEXT? IVUS evaluation gives additive information for
predicting 1-year restenotic risk after Zilver PTX implantation.
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1111Distal EEM area was another independent predic-
tor for restenosis. The ﬁnding indicates that a smaller
vessel would be subject to a poorer stent patency.
Similarly, in analysis without IVUS data, a smaller
angiography-evaluated reference vessel diameter was
signiﬁcantly associated with a higher risk of reste-
nosis. However, the variable lost its statistical sig-
niﬁcance after adjustment for IVUS parameters,
suggesting that the evaluation by IVUS would pro-
vide more reliable information.
The other risk factor for restenosis was a smaller
MSA, indicating that lesions difﬁcult to dilate would
be subject to a high restenosis risk. To date, no reli-
able data were available regarding an optimal stent
expansion in FP lesions. The current ﬁnding suggests
that an implanted Zilver PTX with MSA #12 mm2 has a
high risk of restenosis. Future studies will be needed
to validate the usefulness of this cutoff point.
Interestingly, restenotic lesions, including in-stent
stenotic lesions, were not associated with any
elevated risk for loss of patency after DES implanta-
tion. From latest experience and evidence in FP EVT,
non–de novo FP lesions are described as a critical risk
factor for refractory restenosis (7). The current
ﬁnding was in contrast to these previous experiences,
implying that the Zilver PTX might resolve this crit-
ical issue of rerestenosis.
The current study demonstrated that the predic-
tive ability for restenosis, assessed by the area under
the ROC curve, was statistically improved when IVUS
data were used in addition to angiographic data.
It is possible that IVUS provides more detailed and
precise information on pre- and post-treatment vessel
characteristics than angiography does. The current
ﬁndings suggest that IVUS offers some help in pre-
dicting future risk of restenosis after DES implanta-
tion. However, the predictive ability did not seem
to reach the level that was previously reported in
coronary intervention (9,10). There remains room to
improve the predictive ability for restenosis in FP
intervention.
The 1-year ST incidence was 2%. It is of clinical
note that the cumulative ST incidence rate did not
reach the plateau but was linearly increased even
after 3 months. Identiﬁcation of its risk factors is
needed. In addition, the current study, conducted in
clinical settings, included a few patients interrupting
antiplatelet therapy after DES implantation and
observed that the interruption markedly increased
the ST risk. The importance of continuing antiplatelet
therapy was reconﬁrmed.
STUDY LIMITATIONS. First, the current study
included only Japanese patients, and results shouldbe conﬁrmed in other ethnic groups. Second, this
study was not designed to compare the durability of
Zilver PTX implantation with other treatments. It re-
mains to be studied whether Zilver PTX implantation
is superior to other treatments in real-world settings.
Third, IVUS was not performed for all cases.
In addition, it was manually used for lesion assess-
ment. However, we believe that little heterogeneity
existed in usage and evaluation of IVUS, based on a
common agreement in clinical practice of coronary
intervention.
Fourth, the IVUS assessment in initial treatment
and the DUS assessment for restenosis were not
conducted under core laboratory review, simply
because we could not raise enough research funds to
conduct them. Although this might undermine the
reliability of restenosis assessment, each partici-
pating site has clinical experience conducting pivotal
trials on nitinol stents for FP lesions. We believe that
these accumulated experiences minimized the vari-
ability. Fifth, the times to restenosis or ST were not
exactly assessed because of variable time intervals
between symptom onset and assessment. Sixth, the
current study enrolled the lesions in which the DES
was successfully deployed; therefore, we were unable
to collect the data regarding the success rate.
CONCLUSIONS
We demonstrated real-world 1-year outcomes after
Zilver PTX implantation for FP lesions, including
challenging cases. Lesion length, EEM area, and MSA
were independent predictors for restenosis.
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